




## Bromantane



NPS SUBCLASS	Stimulant
REPORT DATE	August 20, 2024
SAMPLE RECEIVED	October 19, 2023
SAMPLE TYPE	Toxicology

Preferred Name	Bromantane
Synonyms	N/A
Formal Name	N-(4-bromophenyl)adamantan-2-amine
InChI Key	LWJALJDRFBXHKX-UHFFFAOYSA-N
CAS Number	87913-26-6
Chemical Formula	C <sub>16</sub> H <sub>20</sub> BrN
Molecular Weight	306.2
Molecular Ion [M <sup>+</sup> ]	305
Exact Mass [M+H] <sup>+</sup>	306.0852

# Characterization & Intelligence

The following information was compiled in August 2024 and is subject to change as new research is conducted and as new information becomes available:

**Description:** Bromantane is a novel stimulant described as an actoprotector and psychostimulant with structural similarity to adamantane and memantine.<sup>1</sup> Bromantane was first synthesized for therapeutic use in Russia in the 1980s and has been used as a performance-enhancing drug.<sup>2</sup> Bromantane was first detected in October 2023 by our laboratory and confirmed in March 2024 after acquiring standard reference material.

**Sample Source:** Oakland County Medical Examiner (Pontiac, MI)

**Sample Appearance:** Blood specimen

**Pharmacology:** Bromantane acts on the GABA receptors to strengthen GABA-nergic mediation and inhibits serotonin and dopamine reuptake.<sup>1</sup>

**Toxicology:** Bromantane has been identified in one toxicology case to date at the CFSRE.

**Drug Materials:** Bromantane has not been detected in drug materials to date at the CFSRE.

**Demographics / Geographics:** Toxicology cases originated from Michigan. Bromantane was found alongside novel benzodiazepines (e.g., bromazolam) and traditional stimulants (e.g., methamphetamine).

**Legal Status:** Bromantane is not currently scheduled in the United States.

## References:

- ▶ Cayman Chemical: [Bromantane](#)
- ▶ <sup>1</sup>Oliynyk et al. (2012) [The pharmacology of actoprotectors: Practical application for improvement of mental and physical performance](#)
- ▶ <sup>2</sup>Gill (2017) [Performance-enhancing drugs: A review](#)

**About:** In collaboration with medical examiner and coroner offices, crime laboratories, clinical partners, and other stakeholders, the Center for Forensic Science Research and Education (CFSRE) is documenting first confirmations of NPS through analysis of drug materials and/or toxicology samples. These reports are generated using comprehensive analytical techniques (e.g., GC-MS, LC-QTOF-MS, NMR) and include available information about the new substances identified at the time of reporting, as well as the analytical data generated during testing. Our new drug monographs are intended to assist with the rapid identification of NPS in forensic casework and related disciplines, and should not be used for confirmatory purposes alone.

**Analytical Notes:** All identifications were made based on evaluation of analytical data (GC-MS and LC-QTOF-MS) in comparison to analysis of acquired reference material.

**Acknowledgements:** This report was prepared by Sara E. Walton, Denise Teem, Alex J. Krotulski, Donna M. Papsun, and Barry K. Logan at the Center for Forensic Science Research and Education (CFSRE) at the Fredric Rieders Family Foundation. The authors acknowledge scientists at the CFSRE and NMS Labs for their involvements and contributions. For more information, contact [npsdiscovery@cfsre.org](mailto:npsdiscovery@cfsre.org) or visit [www.npsdiscovery.org](http://www.npsdiscovery.org).

**Funding:** CFSRE's NPS Discovery is supported by the National Institute of Justice, Office of Justice Programs, U.S. Department of Justice (Award Number 15PNIJ-22-GG-04434-MUMU, "Implementation of NPS Discovery – An Early Warning System for Novel Drug Intelligence, Surveillance, Monitoring, Response, and Forecasting using Drug Materials and Toxicology Populations in the US"). The opinions, findings, conclusions and/or recommendations expressed in this publication are those of the author(s) and do not necessarily represent the official position or policies of the U.S. Department of Justice.

**Suggested Citation:** Walton, SE; Teem, D; Krotulski, AJ; Papsun, DM; Logan, BK. (2024) *Bromantane — NPS Discovery New Drug Monograph*, Center for Forensic Science Research and Education, United States.


# Gas Chromatography Mass Spectrometry (GC-MS)

**Laboratory:** Center for Forensic Science Research and Education (CFSRE, Willow Grove, PA, USA)

**Instrument:** Agilent 5975 Series GC/MSD

**Methods:** [GC-MS Method Details](#) & [Monographs](#)

**Sample Preparation:** Standard diluted in methanol





# Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-QTOF-MS)

**Laboratory:** Center for Forensic Science Research and Education (CFSRE, Willow Grove, PA, USA)

**Instrument:** Sciex X500R LC-QTOF-MS

**Methods:** [LC-QTOF-MS Method Details](#) & [Monographs](#)

**Sample Preparation:** Liquid-liquid extraction



**Confirmation Using Drug Standard:** Reference material (Batch: 0531437-8) was purchased from Cayman Chemical (Ann Arbor, MI, USA). The analyte was confirmed to be bromantane based on retention time (sample: 10.88 min vs. standard: 11.06 min) and mass spectral data comparisons.